Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Aidan Fry

With over 20 years of experience of reporting on the global pharmaceutical industry, Aidan focuses in his role as editor of Generics bulletin particularly on commercial, regulatory and legal issues affecting the generic, biosimilar, value-added and OTC medicines industries. This includes in-depth analyses of corporate strategy, legislative changes, legal precedents and product perspectives. He regularly interviews leading industry executives and moderates prestigious events. Aidan also oversees the Global Generics & Biosimilars Awards. Aidan speaks fluent German and has a particular affection for maps.
Set Alert for Articles By Aidan Fry

Latest From Aidan Fry

Viatris Will Tread A Different Path

By merging to create Viatris, Mylan and Pfizer’s Upjohn unit intend to occupy a space between generics players and big pharma by offering a broad array of affordable products all around the world.

Business Strategies M & A

China Commits To Patent Linkage And Extensions In US Trade Deal

The first phase of a major trade agreement just signed by the US and China obliges the latter to implement a system linking pharma patent enforcement to marketing authorization procedures as well as to offer patent-term extensions. 

 
Intellectual Property Trade

Viatris Seeks To Be Gateway For Mid-Sized Products

With a global supply chain and commercial platform, the Viatris entity to be formed by the merger of Mylan and Pfizer’s Upjohn unit wants to be the partner of choice for mid-sized products overlooked by companies focused on blockbusters.

Business Strategies Deals

Teva Boss Delights In European Progress

Ongoing launches, relatively stable market conditions and cost-cutting initiatives are producing record profits from Teva’s European operations, president and CEO Kåre Schultz told delegates to a J.P. Morgan Healthcare Conference.

Europe Business Strategies

China Commits To Patent Linkage And Extensions

The first phase of a major trade agreement just signed by the US and China obliges the latter to implement a system linking pharma patent enforcement to marketing authorization procedures as well as to offer patent-term extensions. 

 
Intellectual Property Trade

Teva Chief Claims Credit For US Stability

By getting out of unprofitable product lines, Teva showed the way for industry to stabilize pricing and value in the US retail generics sector, the Israeli group’s president and CEO Kåre Schultz told investors at a J.P. Morgan conference.

Business Strategies United States
See All
UsernamePublicRestriction

Register